numidargistat
numidargistat: developed by 1 company · 3 clinical trials tracked.
numidargistat evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could numidargistat → CALA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Calithera Biosciences, Inc. (CALA) Oncology and hematology indications | Phase 1 |
Clinical Trials (3)
A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
Primary endpoint: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Primary endpoint: Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Frequently asked questions
Who is developing numidargistat?
numidargistat is being developed by Calithera Biosciences, Inc..
How many clinical trials involve numidargistat?
BioSniper tracks 3 clinical trials involving numidargistat.